Financial Statements — NTSK
Balance Sheet
(in billions USD)| Metric | Q2 2026 | Q1 2026 | Q3 2025 |
|---|---|---|---|
| Cash & Equivalents | 0.22 | 0.21 | 0.98 |
| Short-term Investments | 0.85 | 0.90 | 0.17 |
| Accounts Receivable | 0.19 | 0.14 | 0.13 |
| Inventory | 0.00 | 0.01 | 0.01 |
| Total Current Assets | 1.39 | 1.37 | 1.40 |
| Property, Plant & Equipment | 0.10 | 0.09 | 0.09 |
| Goodwill | 0.06 | 0.06 | 0.06 |
| Intangible Assets | 0.01 | 0.01 | 0.02 |
| Total Non-current Assets | 0.13 | 0.12 | 0.12 |
| Total Assets | 1.71 | 1.69 | 1.72 |
| Accounts Payable | 0.03 | 0.02 | 0.02 |
| Total Current Liabilities | 0.69 | 0.63 | 0.60 |
| Total Non-current Liabilities* | 0.87 | 0.88 | 0.96 |
| Total Liabilities | 1.56 | 1.52 | 1.56 |
| Retained Earnings | (2.86) | (2.75) | (2.57) |
| Total Stockholder Equity | 0.16 | 0.18 | 0.15 |
* Derived from reported values
Income Statement
(in millions USD) (except per-share rows)| Metric | Q2 2026 | Q1 2026 | Q3 2025 |
|---|---|---|---|
| Total Revenue | 220.54 | 201.59 | 184.17 |
| Cost of Revenue | 57.52 | 53.34 | 77.53 |
| Gross Profit | 163.02 | 148.26 | 106.64 |
| Research & Development | 101.79 | 105.71 | 262.70 |
| Selling, General & Admin | 45.11 | 45.60 | 141.04 |
| Total Operating Expenses | 252.82 | 256.99 | 553.61 |
| Operating Income | (89.80) | (108.74) | (446.97) |
| Pretax Income* | (107.70) | (113.44) | (450.00) |
| Tax Provision | 3.12 | 3.06 | 3.07 |
| Net Income | (110.82) | (116.50) | (453.07) |
| Basic EPS | (0.27) | (0.29) | (1.85) |
| Diluted EPS | (0.27) | (0.29) | (1.85) |
* Derived from reported values
Cash Flow Statement
(in millions USD)| Metric | Q2 2026 | Q1 2026 | Q3 2025 |
|---|---|---|---|
| Operating Cash Flow | (16.54) | (53.91) | 19.95 |
| Capital Expenditures | 1.63 | 2.16 | 9.56 |
| Free Cash Flow* | (18.17) | (56.07) | 10.39 |
| Investing Cash Flow | 36.83 | (177.18) | (98.64) |
| Financing Cash Flow | (5.28) | 3.47 | 897.33 |
* Derived from reported values